Because of AI, the new startup flex will be how little VC money you raise
One way to get a big burst of attention for any company: A splashy funding announcement with a big valuation.
What we think we’ll see more of in 2027: Companies announcing that they’re not raising capital. Not because they can’t, but because they don’t need to.
Chris, one of the authors of this piece, is an early case study in a pre-AI era. He was a practicing physician when he started his company, Access Physicians, in 2011. He and his three cofounders had an idea to bring telemedicine to hospitals that had historically been slow to adopt new technology. Given their experience with health systems, they knew that it would take time to pressure test the model, so they didn’t want to raise capital too soon.
It ended up taking eight years to bring the solution to market and scale the technology nationwide. During that time, Chris, a newly minted cardiologist, worked as an every-other-weekend hospitalist to pay the bills. The starting salary he was giving up as a trained cardiologist: $550,000. Most of his peers in medicine thought he had lost his mind.
Reserve Your Spot for Upcoming Webinars!

But it gave the team the freedom to build a business on their own terms. The founders agreed not to take distributions, even as the business grew, and reinvest as much of the revenue as they could. Cash flow hiccups and working capital needs were managed through lines of credit. It was a massive founder sacrifice, but all for a very specific reason.
When the time came to raise money, the founders reached out to a firm they already had a relationship with, Health Enterprise Partners. The company took in $9.3m in funding in exchange for giving up <30% of the company. The founders still retained heavy ownership personally and, perhaps more importantly, control of the company. This was their sole round of financing.
The business was lean with a low burn rate, meaning a small team, and no wiggle room to be cash flow negative. The Northstar was growing at a good, respectable pace that might not have set the world on fire. But it could compound over five years at 42% annually and create meaningful value.
Two years later, in 2021, the company sold for $194 million. It was a great return for all parties, roughly a 5.5x.
How does Chris advise companies and fellow founders these days to achieve similar exits?
Well, he has zero regrets about all the years of bootstrapping. The most underrated benefit wasn’t the dilution avoided or the optionality preserved at exit. It was the clarity. Living in a capital-constrained, starvation-mode environment is brutal, but it forces discipline. Discipline around decision-making and action creates maximal efficiency as there is zero room for wasted time, money, or people.
As he recalled:
“Every day felt existential. To keep that cash flowing, we could not lose customers. We were maniacally focused on what our customers bought and what they told us to improve.”
Capital constraints force companies to focus. The team had to say no to many of the ideas that made it onto the proverbial whiteboard. Most companies will be tempted to chase shiny things, and well-meaning advisors or investors will constantly have suggestions. But learning to say no is crucial, and bootstrapping made that easier.
`Upcoming Sessions
Live conversations with the people shaping healthcare.
Verifying AI in Medicine: Is Healthcare AI Actually Ready for Deployment?
Is AI ready for real-world clinical care? Dr. Zak Kohane and Protege’s Engy Ziedan debate what it takes to safely trust AI in diagnosis and treatment, from benchmark performance and clinical evidence to whether we’re holding AI to a higher standard than humans.
Why Are Hospitals Hiring Chief AI Officers?
As AI moves from pilots into day-to-day healthcare operations, health systems are having to decide who should actually own the
Where are AI Agents Actually Working in Healthcare, and Why?
While the healthcare industry remains locked in a high-level debate over the theoretical potential of artificial intelligence, a select group of
Top Employers Share What Healthcare Startups Need to Know in 2026
As enterprise health purchasers face volatile medical cost trends and tightening operational margins, the standard vendor pitch of "improved clinical efficiency&
Peptide Therapy: Where Do We Go From Here?
Watch the full webinar Peptide therapies have moved from niche biohacking circles into mainstream medicine, reshaping conversations around weight management, metabolic health,
Not everyone can access the top 1% of physicians. Will AI change that?
Historically, top-tier medical expertise was limited by wealth and geography. As AI reshapes healthcare delivery, a vital question emerges: can it democratize intelligence to give everyone access to the caliber of care typically reserved for the top 1%?
Privacy AI and the Future of HIPAA
Watch the Full Webinar As AI reshapes healthcare and more patient data flows beyond traditional clinical settings, the rules governing privacy, access,
What will AI do for employer healthcare and benefits?
Employer healthcare may be one of the most practical — and overlooked — proving grounds for AI.
Hospitals as the new go-to-market, lessons from the trenches
Watch the Full Webinar Health systems are entering a new frontier, one where innovation isn’t optional, and meaningful change requires creativity,